Advertisement
U.S. markets closed

Mydecine Innovations Group Inc. (MYCOF)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0093-0.0051 (-35.42%)
At close: 03:27PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0144
Open0.0001
BidN/A x N/A
AskN/A x N/A
Day's Range0.0001 - 0.0146
52 Week Range0.0001 - 0.6560
Volume7,882
Avg. Volume24,734
Market Cap499,915
Beta (5Y Monthly)3.14
PE Ratio (TTM)N/A
EPS (TTM)-0.8800
Earnings DateMar 29, 2024 - Apr 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MYCOF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MYDECINE INNOVATIONS GROUP INC
    SDGR: Rating increased to a HOLDSCHRODINGER INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • News Direct

    Mydecine Innovations Group Inc. Announces Share for Debt Settlement

    VANCOUVER, BC / TheNewswire / 20 March 2024 -- Mydecine Innovations Group Inc. (CSE: MYCO) (FSE: 0NFA), (OTC: MYCOF) (AQSE: MYIG) (the “Company” or “Mydecine”) announced that it has entered into a ...

  • GlobeNewswire

    Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

    VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two Notice of Allowances by the United States Patent and Trademark Office (USPTO) for compounds from the Company’s MYCO-005 and MYCO-006 families. MYCO-005 Notice of Allowance: Aza-Substituted Psil

  • GlobeNewswire

    Mydecine Innovations Group Announces Director Resignation

    VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, announces that Neil Stevenson-Moore has resigned as a director of the Company. The Company would like to thank Mr. Stevenson-Moore for his contributions to the Company and wishes him well in this future endeavors. The Company